Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omega-3CIPNII phase II study in colorectal cancer adjuvant chemotherapy
ChiCTR2500111535Phase 2Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of omega-3-acid ethyl ester and levocarnitine in chemotherapy-induced peripheral neuropathy (CIPN) and colorectal cancer (CRC) (2 arms), sponsored by Hengrui Therapeutics. Primary endpoints: Incidence of chemotherapy-induced peripheral neuropathy (CIPN) and Severity of chemotherapy-induced peripheral neuropathy (CIPN). Started Nov 2025; status: recruiting.
02
Drugs
omega-3-acid ethyl esterlevocarnitine
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2500111535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111535.